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G protein-coupled receptors (GPCRs) are the largest family of membrane
receptors and major targets for FDA-approved drugs. The ability to quan-
tify GPCR expression and ligand binding characteristics in different cell
types and tissues is therefore important for drug discovery. The advent of
genome editing along with developments in fluorescent ligand design offers
exciting new possibilities to probe GPCRs in their native environment. This
review provides an overview of the recent technical advances employed to
study the localisation and ligand binding characteristics of genome-edited
and endogenously expressed GPCRs.
Introduction
G protein-coupled receptors (GPCRs) are membrane
proteins characterised by seven transmembrane-span-
ning domains, an extracellular N terminus and an
intracellular C terminus. They represent the single lar-
gest family of proteins targeted by FDA-approved
drugs; approximately 35% of all drugs target a GPCR
[1]. GPCRs are widely expressed in all tissues; how-
ever, the expression pattern of individual receptor sub-
types varies extensively between cell types [2]. It is
partly this selectivity of expression by different cell
types that helps account for the tissue-selective actions
of many GPCR-targeted drugs. Individual GPCR
subtypes are often natively expressed at low levels
physiologically [3], and many GPCR subtypes can be
up- or down-regulated in disease states [1]. These fac-
tors make the study of cellular distribution and locali-
sation of GPCRs in their native environment
challenging.
There have been many studies using agonists and
antagonists to probe the function of GPCRs in pri-
mary cells and tissues. However, these experiments rely
on the expression profiling of the receptors in the pri-
mary tissue to clarify that the sample in question
endogenously expresses the given receptor. To combat
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this, techniques have been developed to study GPCR
populations at the endogenous level and in native tis-
sues; these include novel biosensors and probes, pro-
gress in genetic engineering and advanced imaging
techniques. This review will focus on new and emerg-
ing techniques (Table 1, Figure 1) to detect and under-
stand the cellular spatiotemporal organisation of
endogenously expressed GPCRs.
Challenges with studying endogenous
GPCRs
The isolation of specific GPCR genes makes it possible
to introduce human GPCRs into recombinant cells
through transfection, allowing for the detailed study of
specific GPCR subtypes in isolation. These experi-
ments rely on the overexpression of GPCRs as models
to study receptor organisation, ligand binding, and sig-
nalling. GPCRs are often expressed in cellular back-
grounds which do not reflect their natural
environment, and often at expression levels far exceed-
ing those found physiologically. Furthermore, receptor
overexpression results in a shift in the relative abun-
dance of interacting partners, including G proteins, b-
arrestins, and potential dimer partners which are
endogenously expressed in the recombinant cell. These
parameters become important when considering phe-
nomena such as receptor reserve, which can dramati-
cally impact the signalling responses measured in a
particular assay [4]. GPCR overexpression therefore
Table 1. Summary of techniques to detect endogenous GPCRs discussed in this review. Advantages and disadvantages of each technique
are described, alongside examples.
Technique Advantages Disadvantages Example GPCRs
Antibodies Versatile: able to perform many different
assays with the same anti-GPCR
antibody
Can conjugate to fluorescent dyes or
heavy metal ions for microscopy
Retention in vivo achieved through
antibody recycling
Not all GPCRs have specific subtype-
selective antibodies





Nanobodies Easily genetically or chemically modified
Can be purified from bacterial cultures in
large quantities
Improved tissue penetration compared to
full-length antibodies due to smaller size
Can be conjugated to other proteins for
improved binding characteristics or
retention
Low retention in vivo due to glomerular
filtration and excretion
Could be challenging to find
noncompetitive extracellular nanobodies
for peptidergic receptors due to overlap
between extracellular epitopes and the
ligand binding site







CRISPR/Cas9 Simple and efficient modification of target
receptor
Can be used to append reporter tags
(fluorescent, bioluminescent, self-labelling
or epitope) onto target receptor
Can introduce disease-relevant SNPs
GPCR is fused to a tag which may change
its function or stability
Potential for off-target editing of the native
genome
Editing requires suitable location of a
protospacer adjacent motif (PAM)
Requires validation to ensure correct in-
frame editing of target









Can visualise receptor localisation in vitro
Can perform ligand binding assays via
microscopy or via FRET/BRET donor
emission
Requires a selective ligand
Fluorescent ligand occupies ligand binding
site, so functional effects are governed
by the pharmacology of the probe









Labels the target receptor without
affecting the ligand binding site
Can be applied to monitor receptor
trafficking and internalisation
Requires extensive ligand design to
validate
Target GPCR needs to contain suitable






µ opioid receptor [108]
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removes the subtlety inherent in a physiological sys-
tem.
To further add to the challenges of studying native
GPCR expression, quantification of GPCR mRNA
expression does not always correlate with the receptor
expression observed at the cell surface [5]. Sriram et al.
[5] compared the RNA expression of a panel of Gq
coupled GPCRs to their expression at the cell surface,
using increases in intracellular calcium to reflect recep-
tor activation. Several high-throughput RNA quantifi-
cation techniques were studied, with single cell RNA-
seq proving to be the most reliable predictor. How-
ever, techniques with low sensitivity yielded many false
negative results, indicating receptors which were
expressed, but not detected by these high-throughput
assays. This becomes particularly challenging when
accounting for the low endogenous expression of many
GPCRs. The discrepancies between mRNA expression
and protein expression aren’t limited to GPCRs, as a
recent study has shown a discordance between mRNA
and protein enrichment patterns depending on the tis-
sue being examined [6]. Additionally, the presence of
previously unknown GPCR splice variants which may
lead to altered ligand binding characteristics, or even
nonfunctional receptors [7,8], may lead to false posi-
tive results at the mRNA level. These results show that
mRNA expression alone cannot account for the detec-
tion or quantification of endogenously expressed
GPCRs, rather their detection requires quantification
at the protein level.
Traditionally, radiolabelled ligands (radioligands)
have been used extensively to study GPCR pharmacol-
ogy, including in binding assays to determine the bind-
ing affinities and kinetic rate constants for both
radioligands and unlabelled ligands [9]. Radioligands
are ligands which have been modified to include a
radioisotope, such as [3H], [14C], [18F] or [125I] [10].
The specifically bound radioactivity can then be moni-
tored following filtration to separate bound and free
radioligand or with the use of scintillation proximity
beads, using a scintillation counter. Radioligands can
therefore detect the presence of the receptor in ques-
tion. Radioligands have also been used in combination
with positron emission topography (PET) imaging to
Fig. 1. New approaches to tag and study endogenous GPCRs in living cells. These include the use of antibodies, nanobodies, fluorescent
ligands and CRISPR/Cas9 genome editing in combination with confocal microscopy, bioluminescence microscopy, fluorescence correlation
spectroscopy (FCS), bioluminescence (BRET) and time-resolved F€orster (TR-FRET) resonance energy transfer, fluorescence-activated cell
sorting (FACS), highly inclined and laminated optical sheet (HILO) microscopy and the application of NanoBiT complementation.
Figure prepared in ©BioRender (www.biorender.com).
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visualise and label specific GPCRs in vitro and in vivo,
usually in the central nervous system [11–13]. This
approach has been useful for detecting changes in
receptor expression under disease conditions [12].
Additionally, a number of peptides have been used as
radioligands to detect and target their endogenous
receptor in diagnostic settings, such as for the neu-
rotensin receptor 1 [14], and the somatostatin receptors
[15]. However, not all GPCRs have radioligands, such
as recently deorphanised GPCRs, or have radioligands
with sufficiently high affinity to be practical in a radi-
oligand binding experiment, such as with the b3-
adrenoceptor [16]. For these receptors, antibodies are
often the primary means of detecting receptor expres-
sion.
Antibodies are glycoprotein heterodimers consisting
of two identical heavy chains and two identical light
chains linked by disulphide bonds [17]. The N-terminal
region of both heavy and light chains varies between
different antibodies. This region constitutes the vari-
able fragment which recognises the antigen. Antibodies
are versatile tools which often bind to their target with
high affinity. Through the use of labelled secondary
antibodies, they can be used to detect the presence of
a specific protein with a wide range of techniques,
including immunohistochemistry, proximity ligation
assays, immunoblotting, or colorimetric detection with
an ELISA. GPCRs genetically modified with epitope
tags (such as FLAG-, HA- or His-tags) can easily be
detected using antibodies against the relevant tag.
However, the generation of antibodies against unmodi-
fied GPCRs (including endogenously expressed
GPCRs) has several significant hurdles to overcome,
including low cell surface expression, the need for the
GPCR to be expressed in a membrane with the correct
post-translational modifications, and the conforma-
tional heterogeneity of GPCRs [18]. Furthermore,
GPCRs exhibit low immunogenicity, with only the N-
terminal domain and extracellular loops accessible as
potential epitopes for extracellularly targeted antibod-
ies. The generation of intracellular-binding anti-GPCR
antibodies is useful for the detection of receptors in
fixed and permeabilised samples, which would allow
the antibody to access its cytoplasmic epitope, such as
antibodies which bind specific phosphorylated residues
on the C-terminal tail of GPCRs [19]. However, these
intracellular binders still require full characterisation,
and suffer from the issues with low immunogenicity
and antibody generation described above. With their
larger N-terminal extracellular regions, there has been
some success generating functional antibodies targeted
against chemokine GPCRs and class B GPCRs [20–
23]. This has resulted in the FDA approval of GPCR-
targeted antibody therapies for migraine, via targeting
the CGRP receptor [24], and certain T-cell lym-
phomas, via antibody targeting the chemokine CCR4
receptor [25].
Antibodies raised against GPCRs with small N-ter-
minal domains, such as the aminergic family of
GPCRs, remain challenging to produce [26]. This has
resulted in antibodies which lack specificity for their
target, or do not recognise their target receptor in its
naturally folded state [27]. Pradidarcheep et al. [28]
tested antibodies raised against each of the five mus-
carinic and nine adrenoceptors. They found distinctive
immunohistological staining patterns for each anti-
body, but significant nonspecific staining of whole-cell
extracts stably expressing only one receptor when
using western blotting. As an example, antibodies
against the a2B-, b2- or b3-adrenoceptors produced
similar bands on their immunoblots, with significant
binding observed in cell lines not expressing the target
receptor. Similar results were seen comparing commer-
cially available antibodies against the b3-adrenoceptor
[29]. Many anti-GPCR antibodies also demonstrate
batch-to-batch variations and thus, poor experimental
reproducibility. As an example, Grimsey et al. [30]
compared several commercially available antibodies
against the N terminus of the cannabinoid CB1 recep-
tor, and tested them with a wide range of immunologi-
cal techniques. They found batch-to-batch variations
in the degree of staining of the CB1 receptor in brain
sections and when expressed in whole cells. These vari-
ations were compounded with poor species specificity
and high cross-reactivity of these antibodies when ana-
lysing cell lysates with western blots [30].
Issues with GPCR-targeted antibodies can be tack-
led using several approaches. For example, the use of
purified or thermostabilised receptor populations for
immunisation, immunisation of the target receptor
DNA directly into the host organism, or immunisation
with peptide fragments have all yielded antibodies
which can specifically bind their target GPCR [31–33].
These advances have led to the development of novel
GPCR antibodies, providing new opportunities to
visualise endogenous receptor localisation. However, it
is important to consider species differences which may
occur if the target receptor and the receptor used as
the immunogenic stimulus originate from a different
species. This is crucial as the extracellular domains (N
terminus and three extracellular loops), which are the
most immunogenic part of a GPCR, often show low
homology between species [34].
Most biochemical approaches to detect GPCRs
require the sample be immobilised through fixation
which can introduce artefacts, permeabilised to allow
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intracellularly targeted antibodies to access their epi-
tope, or denatured in harsh conditions by reducing
agents prior to analysis on reducing gels. Although use-
ful, these techniques only provide a snapshot of the
receptor population which is frozen in time. The use of
selective antibodies with flow cytometry has facilitated
the real-time detection of endogenously expressed cell
surface proteins on a range of live cell types. Its wider
use to study endogenously expressed GPCRs has been
somewhat limited by the paucity of selective antibodies
available, but has included the detection of the non-
canonical GPCR Mas-related G protein-coupled recep-
tor X2 (MRGPRX2) on human LAD2 mast cells [35],
the formyl peptide receptor 2 (FPR2) on human chon-
drocytes [36], CXCR4 on Jurkat, T lymphoid SupT1
and MT-4 T cells [37] and differential expression on dif-
ferent human leukocytes (T cells, monocytes, neu-
trophils, eosinophils, B cells and NK cells) of the
dopamine receptor subtypes D2, D3, D4 and D5 [38].
The recent expansion in development of well validated
selective tools to study GPCRs (e.g. fluorescent ligands,
nanobodies) will allow flow cytometry to be more
widely used to detect the expression of endogenous
GPCRs in complex samples of heterogeneous expres-
sion (e.g. tumours, immune cells), in addition to allow-
ing comparison to other cell surface protein expression,
potential interactions of GPCRs with other proteins
(cell surface and intracellular) and the study of single
cell GPCR pharmacology in real time, to potentially
reveal molecular mechanisms underlying health and dis-
ease. For example flow cytometry used in conjunction
with fluorescence resonance energy transfer (FRET;
FRET/FACS) has allowed the measurement of protein–
protein interactions of the human and simian immunod-
eficiency virus (HIV and SIV) Vpu protein with the
restriction factor CD137 (Bst-2 or tetherin) that must be
overcome to allow HIV-1 release from infected cells
[39]. Here, FRET/FACS had the advantage of combin-
ing the relative spatial sensitivity of FRET to measure
protein–protein interactions with the much greater
throughput possible with flow cytometry. The high
throughput of flow cytometry has also allowed the
detection and profiling of 363 cell surface antigens (lar-
gely cluster of differentiation markers) into biologically
relevant clusters that have been used to classify a range
of cell types including PBMCs, epithelial cancer cell
lines, melanoma cell lines, leukaemia cell lines and cul-
tured fibroblasts [40]. In the flow cytometry studies that
have investigated disease-relevant GPCRs, decreased
GPR18 expression has been observed on polymor-
phonuclear neutrophils from sepsis patients when com-
pared to healthy volunteers [41]. Flow cytometry
measurements of dual-immunolabelled arginine
vasopressin receptor 1A (AVPR 1A) and atypical che-
mokine receptor 3 (ACKR3) expression in human vas-
cular smooth muscle cells has also supported evidence
that these receptors form heteromers that may underlie
interactions between the innate immune and vasoactive
neurohormonal systems [42].
Alternatively, antibodies can be radiolabelled and
administered to detect GPCRs in vivo. At the time of
writing, two GPCR-targeting antibodies have been
used to image GPCRs in vivo, both targeted against
chemokine receptors. These antibodies were labelled
with [89Zr] and were used to visualise CXCR4 or
ACKR3 expression in murine xenograft tumours using
PET imaging [43,44]. Additionally, ACKR3 was visu-
alised in these tumours with an [125I] radiolabelled
antibody [44]. While these studies are impressive, the
lower resolution of PET does not allow for the cellular
localisation of the receptors to be studied.
Single-domain antibodies to
interrogate endogenous GPCRs
In the last few years, single-domain antibody frag-
ments (sdAbs) have emerged as interesting tools to
study GPCR localisation and pharmacology. These
sdAbs are derived from the variable region of heavy
chain-only antibodies, which are found in camelids
(nanobodies) or in cartilaginous fish (VNARs) [17,45].
Nanobodies are small, being only 12–15 kDa in size as
they lack the corresponding light chain found in con-
ventional mammalian antibodies. They retain the high
affinity binding which is characteristic of antibodies;
but unlike full-length mammalian antibodies, they
require no post-translational modification and can
easily be purified in large quantities through expression
in Escherichia coli [17]. Encoded by a single exon, they
can be readily genetically modified with epitope or flu-
orescent tags [46], or alternatively modified chemically
such as via sortase-mediated labelling [47]. Addition-
ally, due to their elongated CDR3 loop, they are par-
ticularly suited for binding concave or cryptic epitopes
[45,48]. One example of such an epitope would be the
nanobody Nb80, for which the concave epitope is
formed by the intracellular loops of the b2-adrenocep-
tor [49]. Over the past 10 years, an increasing number
of GPCR-directed nanobodies have been described tar-
geting the extracellular and intracellular regions of the
receptor [46]. Although no examples have been specifi-
cally described, recent advances in generating synthetic
nanobody libraries [50,51] may prove successful in gen-
erating nanobodies with sufficiently long CDR3 loops
to access with the ligand binding pocket within the
transmembrane domain of GPCRs.
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The majority of nanobodies that bind to the extracel-
lular regions of GPCRs target peptide receptors, with
recent examples detecting the parathyroid receptor
(PTH1R) [52], chemokine CXCR2 receptor [53], and
atypical chemokine receptor 3 (ACKR3) [54]. In addi-
tion, several nanobodies targeted against extracellular
epitopes on the chemokine CXCR4 receptor have been
described [55–58], as well as a panel of i-bodies: human
sdAbs derived from a VNAR scaffold [59,60]. These
studies offer prime recent demonstrations of the utility
of sdAbs for endogenous GPCR detection and their use
as probes for receptor pharmacology [61]. As an exam-
ple, members of the Smit group produced a series of
nanobodies against CXCR4 [57,58]. These nanobodies
were fused to the Fc domain of a human IgG1 antibody
(Nb-Fc) in order to increase their binding affinity and
their ability to perform antibody-mediated effector
function [57]. Using flow cytometry, Nb-Fc fusions were
able to detect endogenous CXCR4 receptors on cells
with low (HEK293T), moderate (Jurkat) and high
(CCRF-CEM) levels of expression. One of these
CXCR4-targeted nanobodies was modified with a small
peptide tag (HiBiT) for further characterisation of the
Nb-CXCR4 interaction [62]. In the presence of exoge-
nous complementary LgBiT, the HiBiT and LgBiT
reconstitute to form the full-length luciferase NanoLuc
and produce luminescence [63]. Using complemented
luminescence, nanobody binding was detected in Jurkat
cells, which could be displaced by the addition of che-
mokine receptor ligands [62]. This approach also
allowed a comparison of the endogenous CXCR4
expression levels with those of a HEK293 cell line
exogenously expressing CXCR4. Griffiths et al. [59]
produced a panel of ‘i-bodies’ which were highly specific
for CXCR4. One of these (AD-114) was used to show
an altered and increased CXCR4 expression pattern in
lung biopsies taken from patients with idiopathic pul-
monary fibrosis [60]. These data demonstrate the poten-
tial for sdAbs to be used to assess differences in GPCR
expression patterns in disease.
Nanobodies have also been used to target endoge-
nously expressed GPCRs on specific cells for photody-
namic therapy (PDT). This technique seeks to
eradicate tumour cells through the local activation of a
photosensitizer with near-infrared light [64]. Heukers
et al. [65] generated a nanobody against the viral
GPCR US28. US28 is constitutively active in glioblas-
toma tumours and causes rapid acceleration of
glioblastoma progression in a murine in vivo model.
This nanobody showed high affinity for US28, binding
the N terminus and ECL3, and could detect this recep-
tor endogenously expressed in glioblastoma. De Groof
et al. [66] modified this nanobody with the near-
infrared dye IRDye700DX to determine if nanobody-
targeted PDT was a viable approach to combat
glioblastoma. The labelled nanobody accumulated
inside US28-expressing cell spheroids, resulting in a
90% reduction in cell viability in these spheroids upon
illumination. Crucially, no change in cell viability was
observed in US28-negative spheroids. Nanobody-tar-
geted PDT was equally efficacious in both 2D and 3D
cell culture models of glioblastoma [66]. This supports
the increased tissue penetrance of nanobodies com-
pared to their bulkier conventional antibody counter-
parts. This study shows the potential for nanobodies
targeted against endogenously expressed GPCRs to be
used to treat certain diseases.
Application of genome-editing
approaches to monitor endogenously
expressed GPCRs
Fusion of genetically encoded tags to GPCRs has
greatly enhanced our understanding of receptor func-
tion in live cell models. Using a diverse range of reporter
tags, for example fluorescent or bioluminescent proteins
or epitope tags, these approaches have been powerful
tools to investigate various aspects of GPCR function
including their cellular localisation, organisation and
signalling. However, due to the technical complexity of
engineering the native genome, as well as limitations on
the ability to detect lowly expressed proteins, these stud-
ies have largely been performed in model cell systems
with over-expressed receptors. Over the last decade, the
discovery that endonucleases such as transcription acti-
vator-like effector nucleases (TALENs) and particularly
the CRISPR/Cas9 system can be harnessed for site-
specific DNA cleavage has greatly simplified the manip-
ulation of the endogenous genome.
As reviewed previously, CRISPR/Cas9 genome-engi-
neering has now been widely used to investigate the
contribution of different signalling pathways following
GPCR activation via knockout of specific signalling
effectors or scaffolding proteins [67]. However, these
genome-editing approaches can also be used to knock
fluorescent or bioluminescent reporters into the native
genome. An advantage of the genome-editing
approaches employed thus far is that only the reporter
component is required to be inserted into the genomic
locus of the GPCR of interest, rather than the need to
add an additional copy of a GPCR with the reporter
or the prior knockout of the endogenous receptor.
Therefore, with this approach, provided that the
GPCR or protein of interest is normally expressed in
the cells used, expression of the fusion protein occurs
under endogenous promotion and is therefore
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maintained close to native expression levels. While
knock-ins allow investigation of tagged proteins in
their native cellular environments without the need for
exogenous expression, only a few studies have used
these approaches to detect GPCRs or investigate their
function. Of these, most reports have used CRISPR/
Cas9 genome editing to insert the luciferase NanoLuc
(or small self-complementing fragments of NanoLuc,
NanoBiTs) into the native genome. This approach has
allowed native receptor expression to be quantified by
luminescence output as well as receptor localisation to
be observed by bioluminescence imaging [68,69]. In
part, a key to these studies has been the use of the
Nanoluc, which due to its brightness provides the sen-
sitivity to detect low levels of natively expressed pro-
teins. Furthermore, by using CRISPR/Cas9 to fuse
NanoLuc to the N terminus of a GPCR, several stud-
ies have now used NanoBRET to investigate binding
of fluorescent and/or unlabelled ligands [70] to natively
expressed GPCRs including genome-edited adenosine
A2B receptors [71], b2-adrenoceptors [68] as well as
CXCR4 and ACKR3 chemokine receptors [69]. These
NanoBRET ligand binding assays appear particularly
suited to genome-editing approaches as the amount of
BRET acceptor, that is a fluorescently tagged ligand,
is exogenously applied and easily adjusted. Other
aspects of GPCR function previously investigated
using over-expressed GPCRs and NanoBRET or
Nanoluc complementation have now also been exam-
ined using genome-edited receptors. This includes
monitoring receptor internalisation [68], GPCR-protein
interactions [69] and formation of GPCR-complexes
[72].
In addition to luminescent tags, CRISPR/Cas9 has
been used to insert fluorescent tags into the native gen-
ome to monitor natively expressed proteins, including
those that facilitate GPCR signalling [73], by fluores-
cence microscopy. An important limitation with this
approach is the ability to detect the relatively low
levels of endogenous GPCR expression found in most
cells without the signal amplification achieved by anti-
body-based approaches. However, a recent study [74]
using CRISPR/Cas9 genome editing to fuse photo-
switchable fluorescent proteins, mEos3.2, mEos4b,
mEGFP or Halotag (subsequently labelled with Janelia
Fluor 549) to CXCR4 expressed under endogenous
promotion allowed single-molecule detection and clus-
ter analysis of tagged CXCR4 to be observed using
super-resolution photo-activated localisation micro-
scopy (PALM). This study also demonstrated
improved detection specificity of natively expressed
receptors when using fluorescently tagged genome-edi-
ted receptors compared to those labelled with
antibodies. They further showed improved sample con-
sistency compared to over-expressed receptors that
allowed for the quantitative measurement of changes
in cluster size and distribution on ligand treatment.
These genome-editing approaches are an important
step forward in our ability to detect and monitor
natively expressed GPCRs. However, the effect of
inserting a tag into the native genome needs to be
assessed as this may alter the levels of protein expres-
sion. Notably, previous studies have demonstrated
small changes in receptor expression, primarily reduc-
tions in expression due to the fusion of full-length
NanoLuc to CXCR4 expressed in HEK293 or HeLa
cells [69]. Additionally, while not specific to genome-
edited GPCRs, tag-dependent changes in expression
following genome editing have also been noted, with
both increases and decreases in expression observed
depending on the tag used [69,74]. However, such
changes are orders of magnitude smaller than that seen
with over-expressed receptors; indeed, studies investi-
gating genome-edited CXCR4 or adenosine A2B recep-
tors found expression to be 40–100-fold lower than
routinely achieved in over-expressed models [71,75]. In
addition to protein expression, and as with any fusion
protein whether genome-edited or over-expressed, tag-
ging a GPCR with a reporter component may change
its function and needs to be assessed to ensure the rel-
evant observations. While such changes need to be
determined empirically, thus far fusion of tags to
receptors or proteins that have been validated in over-
expressed models appear to maintain function when
expressed under endogenous promotion. Fusion of
NanoLuc to the N terminus of CXCR4 maintained
ligand binding properties [69], while C-terminal fusions
to CXCR4 displayed the expected signalling properties
[74,75], recruitment of b-arrestin and internalisation
[68,75]. Similarly, NanoLuc to the N terminus of ade-
nosine A2B receptors maintained ligand binding and
signalling [69]. A further consideration of these
approaches is that so far, these studies have been per-
formed principally on immortalised cell lines
(HEK293, HeLa and PC-3) that are relatively easy to
manipulate via genome editing. It is likely that appli-
cation of these approaches to primary cells or knock-
in animals will further improve our understanding of
GPCRs in their native environment.
Fluorescent ligands and imaging
modalities to study endogenous
GPCRs
As one of the inherent properties of a GPCR is to
bind a small molecule or peptide, an alternative
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method to detect endogenously expressed receptors is
with fluorescently labelled GPCR ligands. Fluorescent
ligands are comprised of an agonist or antagonist for
the receptor of interest which is chemically linked to a
fluorophore. Their design and application in heterolo-
gously expressing systems has been extensively
reviewed elsewhere [76,77]. Fluorescent ligands have
been in use since the 1980s to study GPCRs expressed
endogenously in cell lines and tissues [78–80]. Early
fluorescent ligands were hampered by high levels of
nonspecific binding, dramatic decreases in affinity
compared to parent compounds and poor spectral
properties for use with the then existing detection
methods [81–83]. Improvements in the rational design
of fluorescent ligands [84,85] and the development of
sensitive microscopy technologies have enabled fluores-
cent ligands to be used to study a number of endoge-
nously expressed GPCRs.
One of the main challenges faced when studying
endogenous GPCR expression through imaging
modalities is the poor signal to noise ratio [86]. While
ongoing developments in fluorescent probe chemistry
have provided more selective and brighter ligands,
these can still display high nonspecific labelling which
adds to the background detection noise. Advanced
imaging techniques have been employed to reduce
background fluorescence noise alongside granting
both high temporal and spatial resolution to decipher
GPCR functional dynamics [87–89]. Highly Inclined
and Laminated Optical sheet microscopy (HILO) [90]
selectively illuminates only a thin plane as a result of
a sharply angled laser which can penetrate ~ 10 µm
into the cell. HILO has been employed to study the
endogenous thyroid stimulating hormone receptor
(TSHR) within primary mouse thyroid cells. Away
from the typical model of membrane restricted GPCR
signalling, the TSHR has previously been demon-
strated to stimulate signalling cascades postinternalisa-
tion, but only in over-expressed systems [91]. By using
a fluorescently labelled thyroid stimulating hormone
(TSH) and HILO microscopy, agonist-bound endoge-
nous TSHR was detected at both the plasma mem-
brane and the trans-Golgi network [88]. The selective
illumination of a sharp plane of light to reduce back-
ground noise not only allowed detection of low sig-
nals typical of endogenous studies but also allowed
fast acquisition to capture these real-time and poten-
tially short-lived events. The data obtained with
HILO, supported by the use of a fluorescently tagged
nanobody biosensor, suggested direct activation of G
proteins by the TSHR within the trans-Golgi net-
work, highlighting a physiological role for intracellu-
lar signalling [88].
Fluorescence correlation spectroscopy (FCS) is
another powerful technique which maximises signal to
noise through the measurement of fluorescence fluctua-
tions emanating from a confocal observational volume
(~ 0.25 fL). When placed on the cell membrane, the
analysis of the fluorescence fluctuations within this vol-
ume can inform on receptor organisation and cluster-
ing [92]. Endogenously expressed histamine H1
receptors in HeLa cells were examined using FCS
through recording the fluctuations in the presence of a
fluorescent histamine H1 receptor antagonist, mepyra-
mine-BODIPY-630/650 [87]. Both specific binding to
the endogenous histamine H1 receptor and nonspecific
membrane binding displayed differing diffusion speeds
to those recorded in CHO cells stably overexpressing
the histamine H1 receptor. This suggested a cell type-
specific macromolecular organisation of the receptor.
Furthermore, differences between the nonspecific bind-
ing measurements suggested there were differences in
the organisation of the plasma membrane in these two
cell lines. It was postulated that the HeLa plasma
membrane environment may be lipid-raft free, or con-
tained a receptor population which was less con-
strained than those within the CHO cells. The high
temporal resolution of FCS (µs–ms) coupled with
selective and bright fluorescent ligands holds the power
to interrogate the dynamics and organisation of
GPCRs within nanodomains. Using this technique to
study endogenous receptor population can avoid
forced events and artefacts caused by receptor overex-
pression [93].
As demonstrated above, fluorescent ligands can be
versatile tools to study GPCRs expressed in endoge-
nous systems. Recent improvements in fluorescent
ligands with improved subtype selectivity, affinities
and physicochemical properties, has made them a valid
alternative to antibodies to specifically detect endoge-
nous GPCRs in flow cytometry studies. For example,
fluorescently labelled CXCL12 has been used to iden-
tify CXCR4 positive T lymphoid SupT1 cells [94].
Additionally, the use of a fluorescent cannabinoid CB2
receptor ligand (NMP6) identified expression of the
CB2 receptor on CD4+ T cells [95] which was pre-
vented by preincubation with a CB2 selective agonist.
In another example, adenosine A3 receptors were
shown to be aggregate in immunomodulatory micro-
domains on neutrophils using the fluorescent adeno-
sine ligand CA200645 [96]. Fluorescent ligands also
have the advantage of allowing the multiplexing of
receptor detection alongside quantification of receptor/
ligand target engagement at equilibrium in respect to
ligand affinity, selectivity, binding kinetics and func-
tional signalling outputs. Flow cytometry has been
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used to quantify the specific binding of an adenosine
A3 receptor agonist (MRS5218) in human promyelo-
cytic leukaemia cells [97] that was displaceable by
unlabelled adenosine A3 receptor selective antagonist.
Specific binding of fluorescently labelled histamine
(BODIPY-histamine) to the murine histamine H2 or
H4 receptor subtypes in Chinese Hamster Ovary
(CHO) and murine bone marrow derived mast cells
(mBMMCs) has also been shown using flow cytometry
and also revealed upregulation of the H4 subtype on
mBMMCs in response to immunoglobulin E treatment
[98].
A major advantage of using flow cytometry to quan-
tify receptor/ligand engagement is the decreased need
for separation of free fluorescent ligand in solution
from ligand that is receptor bound, a factor that is
critical to other measurements of ligand binding. This
is a consequence of the narrow sample volume used so
that only a small volume of sample fluid that sur-
rounds the cell is excited. This minimises excitation of
unbound fluorescent molecules that are also in solu-
tion, diminishing the background fluorescence signal
[99]. Sklar et al. [80] took advantage of this fact to
perform competitive binding kinetic studies of the for-
myl peptide receptor endogenously expressed on neu-
trophils. However, the low endogenous expression of
GPCRs results in low fluorescence emission levels
detected per cell. There are practical limits in flow
cytometry for detection of low fluorescence emissions
in order to distinguish from cell autofluorescence,
although improved instrumentation has aided this dis-
tinction [100]. The sensitivity and rapidity of flow
cytometry measurements in conjunction with the abil-
ity to measure multiple pharmacological parameters
simultaneously, therefore makes flow cytometry an
attractive method for detecting and characterising the
molecular pharmacology of endogenous GPCRs.
Advances in fluorescent ligand design and synthesis,
such as the tuning of the physiochemical properties of
the linker region to improve ligand affinity and solu-
bility, have made it possible to image GPCRs in vivo.
An infrared-emitting a1-adrenoceptor antagonist was
designed by Ma et al. [101], and used to label endoge-
nous a1-adrenoceptors in ex vivo slices of murine pros-
tate tissue. This fluorescent ligand was administered
intravenously in mice as a way to image the distribu-
tion of a1-adrenoceptors in several tissues. This tech-
nique represents a simple and noninvasive way to
detect receptor localisation without the need for
lengthy and costly RNA-seq or northern blotting.
Recently, Ast et al. [89] described the use of two-
photon microscopy alongside a panel of fluorescently
labelled GLP-1 agonists (LUXendins) to localise
endogenous GLP-1 receptors in mice. These fluores-
cent ligands displayed exceptional signal-to-noise ratios
with good affinities for the GLP-1 receptor. They
revealed a distinctive pattern of GLP-1 receptor
expression in murine a-cells in pancreatic islets, which
is important for understanding the action of incretin
mimetics in the clinic. Additionally, the good imaging
characteristics of these ligands made them amenable to
super-resolution approaches to study subcellular recep-
tor localisations. The GLP-1 receptors were found to
cluster in nanodomains in pancreatic b-cells, which
may have implications for the activation and signalling
of these receptors in vivo.
Esteoulle et al. [102] designed a fluorescent ligand
for the oxytocin receptor with a near-infrared-emitting
dimer moiety. The fluorogenic dimer was designed to
be quenched in the aqueous environment of the extra-
cellular medium, but fluoresce strongly in the
hydrophobic environment of the lipid bilayer, or when
bound to the receptor. Through binding experiments
with unlabelled oxytocin antagonists, this fluorescent
ligand was found to specifically bind the oxytocin
receptor over-expressed in HEK293 cells [102]. More
interesting was the use of this ligand to image murine
oxytocin receptors in vivo in lactating mice. The ligand
showed strong fluorescence in mammary glands,
indicative of the presence of oxytocin receptors, with
extremely low background fluorescence. The authors
suggest this approach could be used for other ligands
as a noninvasive method to visualise other GPCRs in
their native environment.
Covalent approaches to label
endogenous GPCRs
Fluorescent ligands, by their design, do not react with
the receptor of interest and can freely associate and
dissociate from the receptor-binding pocket. This is
advantageous when fluorescent ligands are used as
probes in ligand binding assays but for studying recep-
tors at endogenous levels, it would be favourable to
permanently label the receptor with a fluorophore.
Two recent studies have utilised bioorthogonal chem-
istry to attach a fluorophore to a ligand that is cova-
lently bound to either the adenosine A2A receptor
[103] or the cannabinoid CB2 receptor [104]. In this
two-step process, first, a ligand with an alkyne handle
is covalently bound to the receptor of interest, and
then upon photoactivation a fluorescent label is
attached to the alkyne handle. This second reaction is
classed as a bioorthogonal reaction, which are very
selective and do not cross-react with biological matter
present within the experimental set up. The use of
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bioorthogonal reactions to label GPCRs has the
potential to overcome some of the issues of nonspecific
binding associated with fluorescent ligands, but to date
this has not been investigated. In addition, as the pho-
toaffinity ligand is covalently linked to the receptor of
interest, this prevents the addition of subsequent
ligands to probe the function of the receptor. Only the
photoaffinity probe for the CB2 receptor has been used
to label endogenously expressed receptors. The CB2
receptor is a target for chronic and inflammatory pain
[105] and there is a need to determine if the CB2 recep-
tor is upregulated in specific immune cell types. With
this in mind, the photoaffinity probe was used to
investigate the expression of the CB2 receptor in
peripheral blood mononuclear cells using FACS analy-
sis. The probe detected the highest specific binding in
CD19+ B cells which was confirmed by qPCR analysis
of CB2 receptor mRNA levels. Importantly the probe
could distinguish differences in expression levels as for
other immune cell types (CD14+ monocytes, CD3+ T
cells) both the specific binding of the photoaffinity
probe and mRNA levels was lower than in CD19+
cells [104]. Therefore, this photoaffinity ligand has the
potential to probe CB2 expression levels in different
disease states.
An extension of photoaffinity labelling utilises
ligand-directed chemistry to covalently label a receptor
of interest without affecting the ligand-binding site. In
ligand-directed chemistry, a label is connected via a
highly reactive, electrophilic linker to a ligand that
binds to the receptor of interest. Upon binding of this
conjugate, the linker can undergo a substitution reac-
tion with a nucleophilic amino acid side chain, forming
a new covalent bond between the label and receptor
and consequently separating the ligand from the label
[106]. This approach has been successfully applied to
label three GPCRs so far; the bradykinin B2 receptor
with biotin [107], and the l opioid and adenosine A2A
receptor with a fluorophore [108,109]. As the ligand is
separate from the fluorophore after labelling, it is, in
principle, able to freely dissociate from the receptor,
and should leave the binding site intact to be probed
by additional ligands. This has led ligand-directed
labelling to be known as traceless labelling, and has
been shown to be true for the three receptor examples
above. An early study which attempted to incorporate
a small label into the adenosine A2A receptor in a
ligand-directed manner found that these compounds
reduced the number of binding sites available for a
radiolabelled ligand, essentially blocking the receptor
binding site [110]. Therefore, for each new ligand
developed the impact on the ligand binding site will
have to be confirmed.
To date, ligand-directed labelling has been used to
label endogenously expressed adenosine A2A receptors
and l opioid receptors. The adenosine A2A receptor is
a target for cancer immunotherapy as it is highly
expressed on immune cells [111]. Endogenously
expressed A2AR was detected using FACS analysis on
human monocyte-derived macrophages and visualised
on a human breast cancer cell line using confocal
microscopy [109]. The ligand-directed label described
for the l opioid receptor has been used to map opioid-
sensitive neurons in rat and mouse brains. Due to the
function of the receptor being preserved after labelling,
agonist-mediated internalisation was visualised in locus
coeruleus neurons [108] and understanding the expres-
sion pattern and responsiveness may aid the develop-
ment of safer analgesics that target this receptor [112].
Ligand-directed labelling of GPCRs offers a noninva-
sive approach to visualise receptors and opens up a
huge number of possibilities to study ligand binding,
receptor trafficking and signalling in endogenously and
clinically relevant systems.
Summary and future directions
The approaches discussed above demonstrate the rapid
advances being made to detect endogenous GPCRs in
their native environment. Improvements in fluorescent
ligand design will result in more studies describing the
subcellular GPCR localisation and how this may
change in response to cellular stress. These approaches
could also be used in conjunction with advanced
microscopy (Table 2), such as single-molecule tracking
or FCS, to probe the role of GPCR dimerisation and
organisation into higher order oligomers in their native
environment. Additionally, the recent studies using flu-
orescent ligands in vivo are particularly exciting, as
these demonstrate the possibility to investigate recep-
tor distribution in disease models.
GPCRs are now known to be capable of signalling
from intracellular compartments, such as from the
endosome or trans-Golgi network [88,113,114]; how-
ever, only a few studies have shown this to be the case
for endogenously expressed GPCRs. This is important
as the trafficking and organisation of GPCRs can
change depending on the expression level [115]. The
techniques discussed above could expand on this
knowledge to determine if this compartmentalised sig-
nalling occurs for a subset of GPCRs, or is a widely
occurring phenomenon. CRISPR/Cas9 offers the abil-
ity to introduce disease-relevant single nucleotide poly-
morphisms (SNPs) and study their effects in relevant
cellular or animal models. However, at the time of
writing few studies have used this approach, with
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Table 2. Current and evolving microscopy techniques for studies with GPCRs expressed at endogenous levels. Advantages and




























FCCS – Fluorescence Cross-Correlation
Spectroscopy. Separate and combined
diffusion properties of two different
fluorophores can be resolved allowing
investigation of protein–ligand and protein–
protein interactions, e.g. dimerisation.
Scanning FCS – Observation volume is
scanned repeatedly across the sample to
record diffusion at multiple locations
HILO Thin imaging plane







Limited field of view
Cannot penetrate deep
samples
TSHR [88] TIRF – Total Internal Reflection
Fluorescence microscopy. Evanescent
wave only excites fluorophores within
~ 100–200 nm of coverslip surface ideal to
study membrane localised proteins.
LSFM – Light Sheet Fluorescence
Microscopy. The field of view is imaged
perpendicular to a thin sheet of laser
excitation. This leads to reduced
background from out of focus
fluorescence, increased signal-to-noise and
faster acquisition. Much larger sample,
















CXCR4 [69] BRET imaging – Imaging of the resonance
energy transfer from luciferase to
fluorescent protein or ligand linked
fluorophore can enable the study of









fixed and live samples
and almost all probes
Low signal to noise
















applications are now possible which allow
capture of single-molecule localisation and
high spatial resolution (See below).
FRET – Forster Resonance Energy
Transfer. Protein–protein and protein–
ligand interactions can be detected
through measuring the fluorescence of a

























STORM – STochastic Optical
Reconstruction Microscopy.
Reconstruction of stochastically activated
photo-switchable fluorophores to detail
precise localisation data. Could potentially
utilise fluorescently tagged GPCR
antibodies or nanobodies.
Expansion Microscopy. Physical
enlargement of a specimen attached to a
polymer to allow nanoscale imaging with a
standard confocal microscope
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examples including the b1-adrenoceptor [116], and the
orphan receptor GPRC6A [117]. Given the variation
of the GPCR repertoire in a patient population [118],
understanding the role SNPs have on endogenous
receptor expression and function could offer important
targets for personalised medicine. Additionally, the
combination of CRISPR/Cas9 and FRET/BRET tech-
niques offers the potential to study ligand–receptor
interactions at endogenous levels in primary cells.
Studying endogenously expressed GPCRs in native
conditions could lead to the development of novel
biomarkers or drug targets previously overlooked.
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